Skip to content
Brand AI

DaShenLin Pharmaceutical Group Co., Ltd.

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2024

    Maoming subsidiary and controller unit bribery case: first-instance conviction and penalties

    In 2024, DaShenLin disclosed that its Maoming subsidiary was convicted of unit bribery and fined RMB 4 million, while one of the actual controllers, Ke Jinlong, received a first-instance sentence of 3 years and 6 months plus a RMB 500,000 fine. The company said the matter involved the subsidiary's historical wholesale business and did not conflate the litigation entity with the parent company.

    Source